GI Oncology Expert Tumor Board: Leveraging Immune Biomarker Reports and Trial Evidence to Coordinate Care at Key Decision Points

Release Date: January 29, 2021
Expiration Date: January 29, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in gastrointestinal cancers. In this educational program, these experts review key data regarding biomarker assessment and interpretation, as well as clinical trial data for biomarker-guided treatment options. Through a combination of didactic presentations and case-based panel discussion, the data are placed in the context of clinical scenarios to aid in interpreting emerging data. With a focus on microsatellite instability/mismatch repair deficiency and PD-L1 expression, the panel reviews testing methodologies and interpretation of results that guide the role of current and emerging immunotherapy treatment options for patients with gastrointestinal tumors.

This educational activity is an archive of the live virtual symposium held on January 15, 2021.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Target Audience

This educational program is directed toward medical oncologists, surgical oncologists, radiation oncologists, and gastroenterologists interested in the treatment of gastrointestinal (GI) cancers. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment of patients with GI cancers are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Explain the rationale for the biomarker-informed use of immunotherapeutic agents in patients with GI cancers
• Evaluate the most recent clinical trial data on biomarker-guided immunotherapies in GI cancers
• Apply evidence from biomarker-driven immunotherapy trials to real-world case scenarios in the management of patients with GI cancers
• Implement proactive strategies to monitor and mitigate potential adverse events related to immunotherapeutic agents in patients with GI tumors

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Johanna Bendell, MD
Chief Development Officer
Director, GI Cancer Research Program
Director, Drug Development Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, TN

Disclosures: No relevant financial relationships with commercial interests to disclose.

Ryan B. Corcoran, MD, PhD
Director, Gastrointestinal Cancer Center Program
Scientific Director, Termeer Center for Targeted Therapy
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grant Research Support: Asana BioSciences, Lilly; Consultant: AbbVie, Asana BioSciences, Astex, C4 Therapeutics, Ipsen, Kinnate Biopharma, Mirati Therapeutics Inc, Natera Inc, Qiagen, Revolution Medicines, Roivant Sciences, Taiho Pharmaceutical; Shareholder: Avidity Biosciences, C4 Therapeutics, Kinnate Biopharma, nRichDx, Remix, Revolution Medicines.

Manish A. Shah, MD, FASCO
Director, Gastrointestinal Oncology Program
Chief, Solid Tumor Service
Co-Director, Center for Advanced Digestive Disease
Professor of Medicine
Bartlett Family Professor of Gastrointestinal Oncology
Weill Cornell Medicine/New York-Presbyterian Hospital
Division of Hematology and Medical Oncology
New York, NY

Disclosures: Grant Research Support: Astellas, Bristol Myers Squibb.

Wells Messersmith, MD, FACP
Professor and Head, Division of Medical Oncology
Associate Director for Translational Research
University of Colorado Hospital Cancer Center
University of Colorado School of Medicine
Aurora, CO

Disclosures: Grant Research Support: (Institutional/Clinical Research): Pfizer, Tanabe, ALX, Gossamer, NGM, Beigene; Other: DMSC for FivePrime, QED.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.